S
Stanley G. Rockson
Researcher at Stanford University
Publications - 231
Citations - 8531
Stanley G. Rockson is an academic researcher from Stanford University. The author has contributed to research in topics: Lymphedema & Lymphatic system. The author has an hindex of 48, co-authored 210 publications receiving 7245 citations. Previous affiliations of Stanley G. Rockson include Duke University & Harvard University.
Papers
More filters
Journal ArticleDOI
Endothelial cell diversity revealed by global expression profiling
Jen-Tsan Chi,Howard Y. Chang,Guttorm Haraldsen,Frode L. Jahnsen,Olga G. Troyanskaya,Dustin S. Chang,Zhen Wang,Stanley G. Rockson,Matt van de Rijn,David Botstein,Patrick O. Brown +10 more
TL;DR: Tissue-specific expression patterns in different tissue microvascular ECs suggest they are distinct differentiated cell types that play roles in the local physiology of their respective organs and tissues.
Journal ArticleDOI
Lymphedema: classification, diagnosis and therapy:
Andrzej Szuba,Stanley G. Rockson +1 more
TL;DR: The diagnostic features, the pathophysiology and the available therapies for lymphedema are presented, which include isotopic lymphoscintigraphy, indirect and direct lymphography, magnetic resonance imaging, computed tomography and ultrasonography.
Journal ArticleDOI
Estimating the population burden of lymphedema.
TL;DR: It is extremely attractive to contemplate that future approaches will entail formal, prospectively designed studies to objectively quantitate incidence and prevalence statistics for individual categories, as well as for the global lymphedema population.
Journal ArticleDOI
Therapeutic lymphangiogenesis with human recombinant VEGF-C
Andrzej Szuba,Mihaela Skobe,Marika J. Karkkainen,William S. Shin,David P. Beynet,Ned B. Rockson,Noma Dakhil,Stan Spilman,Michael L. Goris,H. William Strauss,Thomas Quertermous,Kari Alitalo,Stanley G. Rockson +12 more
TL;DR: The capacity of a single dose of VEGF‐C to induce therapeutic lymphangiogenesis in acquired lymphedema is confirmed, in addition to improving lymphatic function and vascularity, VEGf‐C can apparently reverse the abnormalities in tissue architecture that accompany chronic lymphatic insufficiency.
Journal ArticleDOI
New developments in clinical aspects of lymphatic disease.
TL;DR: The manner in which new knowledge of lymphatic genes and molecular mechanisms has demonstrated that lymphatic dysfunction should no longer be considered a passive bystander in disease but rather an active player in many pathological processes is considered and, therefore, a genuine target for future therapeutic developments.